Skip to main content

Press Releases and Ad-hoc Announcements

16 December 2022	PR: Heidelberg Pharma Signs Research and Exclusive Option Agreement with Binghamton University on Immunostimulatory Technology Platform	PDF
14 December 2022	PR: Encouraging Clinical Data from Two Antibody Drug Conjugates Based on Heidelberg Pharma’s ATAC Technology Presented at the ASH Annual Meeting 2022	PDF
10 November 2022	PR: Heidelberg Pharma and Partner Magenta to Present Initial Clinical Data on their Antibody Drug Conjugates at the ASH Annual Meeting 2022	PDF
07 November 2022	PR: Heidelberg Pharma’s Partner Telix Reports Positive Data on the Pivotal ZIRCON Study	PDF
13 October 2022	PR: Heidelberg Pharma AG: Interim Management Statement on the First Nine Months of 2022	PDF
04 October 2022	AH: Heidelberg Pharma AG Announces Adjustment of Guidance	PDF
09 September 2022	AH: Heidelberg Pharma Announces Conclusion of License Agreement with Partner Takeda To Develop an Antibody Targeted Amanitin Conjugate	PDF
30 August 2022	PR: Heidelberg Pharma AG Raises Approximately EUR 80 Million From Capital Measure	PDF
12 August 2022	PR: Heidelberg Pharma AG Launches Rights Issue of up to EUR 80 Million	PDF
13 July 2022	AH: Heidelberg Pharma and Chiome Bioscience Sign Exclusive, Target-Specific Research and Option Agreement for the Development of an Antibody Drug Conjugate	PDF
12 July 2022	PR: Heidelberg Pharma Reports on First Half-Year 2022	PDF
28 June 2022	PR: Heidelberg Pharma Reports Outcome of the Annual General Meeting 2022	PDF
09 May 2022	AH: Heidelberg Pharma AG and Partner Huadong Receive all Approvals for the Announced Transaction from the Authorities and Plan Capital Measure	PDF
28 April 2022	PR: Heidelberg Pharma AG: Interim Management Statement on the First Three Months of 2022	PDF
07 April 2022	PR: Heidelberg Pharma to Present New Data on its Proprietary ATAC® Technology Platform at the AACR Annual Meeting 2022	PDF
24 March 2022	PR: Heidelberg Pharma Announces Financial Figures for Fiscal Year 2021 and Provides Business Update	PDF
10 March 2022	PR: Heidelberg Pharma Receives Milestone Payment from Partner Magenta for Dosing the First Patient with MGTA-117	PDF
28 February 2022	PR: Heidelberg Pharma and Huadong Announce Strategic Partnership, Including Equity Investment	PDF
27 February 2022	AH: Heidelberg Pharma and Huadong Announce Strategic Partnership, Including Equity Investment	PDF
17 February 2022	AH: Heidelberg Pharma AG Secures Financing Commitment From its Main Shareholder dievini	PDF
15 February 2022	PR: Heidelberg Pharma Announces First Patient Dosed with Antibody Targeted Amanitin Conjugate HDP-101 in Multiple Myeloma	PDF